Medivir AB (OSTO:MVIR)
kr 2.87 -0.08 (-2.71%) Market Cap: 321.92 Mil Enterprise Value: 165.94 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 60/100

Q1 2019 Medivir AB Earnings Call Transcript

May 03, 2019 / 12:00PM GMT
Release Date Price: kr11.95 (+2.19%)
Operator

Ladies and gentlemen, welcome to the Medivir AB Q1 Report 2019. (Operator Instructions) Today, I am pleased to present, Uli Hacksell, CEO. Please begin.

Uli Hacksell;publ;CEO
Medivir AB;President & Director

()- -

Thank you, and good afternoon.

We meet today Lotta Ferm, who is our Interim CFO, and I have Linda Basse, who is our Chief Medical Officer, who will be able to answer any medical questions as well.

Let me move to Slide #2, and I encourage you to read that because it contains information about risk factors, et cetera, that are important to understand.

Let's move to the next Slide #3. We have had an exciting start of 2019 with our zoomed in focus on oncology, on clinical development and on business development. When it comes to the clinical development, we have 2 ongoing studies, which are very exciting for us. A study with a combination of birinapant and Keytruda where we have already recruited 14 patients in our colorectal cancer study and where we expect to have an interim

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot